What does the research say about the senescence-associated secretory phenotype?
The senescence-associated secretory phenotype (SASP) is the pro-inflammatory secretome of senescent cells. Here is what the published literature reports about its composition, its context-dependent roles, and the agents
The senescence-associated secretory phenotype (SASP) is the collective term for the mixture of inflammatory cytokines, chemokines, growth factors and matrix-remodeling enzymes that senescent cells release into their surroundings [2]. It is not a single molecule and has no sequence, formula or molecular weight; it is a phenotype — an output profile — and the literature treats it as a class of secreted factors rather than a defined compound. The defining cellular context is irreversible cell-cycle arrest combined with a pro-inflammatory secretome [5].
The signaling work in this area centres on the NF-κB, mTOR, JAK/STAT and cGAS-STING pathways, which are the nodes most often described as driving SASP induction and maintenance [4].
Research Studies
SASP and tumor microenvironment remodeling
A review of SASP-mediated remodeling of the tumor microenvironment describes SASP as comprising inflammatory cytokines, chemokines, growth factors and matrix-remodeling enzymes that regulate that microenvironment, and frames its role in cancer as condition-dependent rather than uniformly pro- or anti-tumor [2]. The same review covers mechanisms of SASP induction and emerging strategies that target senescent cells and SASP signaling [2].
CCT/TRiC and therapy-induced senescence in glioblastoma multiforme
In glioblastoma multiforme (GBM), standard therapies — maximal resection, radiotherapy and temozolomide — are reported to drive many cells into therapy-induced senescence (TIS), marked by permanent proliferation arrest, high metabolic activity and SASP [3]. The review notes that although senescent cells may initially limit growth, their persistence can fuel recurrence by altering the microenvironment while driving immunosuppression and stem-like traits [3]. GBM is described as chaperone-dependent, relying on proteostasis networks, with the eukaryotic chaperonin CCT/TRiC implicated in that dependence [3].
Senomorphic agents and multi-target SASP modulation
Senomorphic agents are distinguished from senolytics in the literature: rather than eliminating senescent cells, they modulate the SASP while preserving the cells and their potential physiological functions [4]. A review of this class reports multi-target mechanisms, including inhibition of NF-κB, mTOR, JAK/STAT and cGAS-STING, and classifies the agents into three major categories [4].
Circulating SASP biomarkers in human cohorts
When SASP factors are tracked in circulation, they associate with age-related clinical traits and diseases, which the literature raises as a possible route to noninvasively assessing senescence burden in clinical settings [5]. This review consolidates human-focused evidence identifying circulating biomarkers of senescence and covers emerging drug- and lifestyle-based senotherapeutic interventions [5].
SS-31 peptide and radiation-induced cardiomyocyte senescence
The mitochondrial-targeted peptide SS-31 (elamipretide) was evaluated for effects on radiation-induced cell senescence in cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) [6]. Exposure to γ-radiation at 2, 5 and 10 Gy inhibited H9C2 proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase (SA-β-gal) staining [6]. These findings are in vitro.
Piperlongumine and senescent meniscus cells and chondrocytes
In an osteoarthritis model, senescence and SASP marker expression was assessed in meniscus and cartilage of OA-induced rats, and rat meniscus cells and chondrocytes were rendered senescent with H2O2 before treatment with candidate senolytics including piperlongumine (PL) [7]. Transcriptomic analysis was used to explore the PL mechanism [7]. This work is animal and cell-based.
Senolytic-regenerative combination in murine aging models
A combination approach pairing a dendritic cell-based senolytic immunotherapy with syngeneic pluripotent stem cell-derived mesenchymal stem cells was tested in two murine models: carbon tetrachloride-mediated liver injury and doxorubicin-induced systemic senescence [8]. The stated rationale was that SASP factors exert anti-regenerative effects and that senescent cell burden must be reduced to overcome them [8]. These findings are animal-only.
Bone aging as a multiscale degenerative process
A review of bone aging characterizes it not merely as bone mass loss but as a multi-level, networked degenerative phenomenon spanning molecular, cellular, tissue and system levels, with declines in bone mass, microstructure and biomechanical properties [1].
Comparison of senolytic and senomorphic strategies
| Strategy | Action on senescent cells | Reported signaling focus |
|---|---|---|
| Senolytics | Eliminate senescent cells | Not specified in the cited review [4] |
| Senomorphics | Modulate SASP without clearing the cells | NF-κB, mTOR, JAK/STAT, cGAS-STING [4] |
If you are reading this for personal health reasons
The materials described here are sold for laboratory research use only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for use in a person. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation — https://europepmc.org/article/PMC/PMC13572547
- [2] A Review of Senescence-Associated Secretory Phenotype-Mediated Remodeling of the Tumor Microenvironment — https://europepmc.org/article/PMC/PMC13572038
- [3] From protection to progression: How CCT/TRiC shapes therapy-induced senescence in glioblastoma multiforme — https://pubmed.ncbi.nlm.nih.gov/42624300/
- [4] Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing — https://pubmed.ncbi.nlm.nih.gov/42498087/
- [5] A compendium of circulating biomarkers of senescence in humans — https://europepmc.org/article/PMC/PMC13408882
- [6] Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence — https://europepmc.org/article/PMC/PMC13400571
- [7] Piperlongumine attenuates knee osteoarthritis progression by eliminating senescent meniscus cells and chondrocytes — https://pubmed.ncbi.nlm.nih.gov/42322814/
- [8] Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan — https://europepmc.org/article/PMC/PMC13244891